RxDoctor Payments Data

Timothy Nguyen, MD

Ophthalmology · Richmond, VANPI 1477014389

Payments from drug & device makers

$1,532in general payments, 2019–2025

Across 47 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$818
  • AbbVie$137
  • Ocular Therapeutix, Inc.$120
  • Tarsus Pharmaceuticals, Inc.$75
  • Notal Vision, Inc.$63
  • Oyster Point Pharma, Inc.$57
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$1,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,532 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$538,500
Medicare patients
1,418
Services billed
5,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$22,740
LumiganBimatoprost26$11,168
RhopressaNetarsudil Mesylate16$9,226
Prednisolone Acetate235$7,465
Latanoprost565$5,294
MoxifloxacinMoxifloxacin Hcl192$4,649
Ketorolac Tromethamine221$3,852
SimbrinzaBrinzolamide/Brimonidine Tart17$3,505
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$2,343
Brimonidine Tartrate141$1,873
Timolol Maleate97$1,148
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$478
Dorzolamide Hcl18$376
Ofloxacin27$327
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$137$33,90844 claims
AlconSimbrinza$818$3,50517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →